Discover how the latest study, ‘GI-SCREEN CRC-Ukit,’ unveils the potential of plasma angiogenic factors to revolutionize second-line chemotherapy for metastatic colorectal cancer patients.
– by Klaus
Note that Klaus is a Santa-like GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study.
Yuki et al., Clin Colorectal Cancer 2024
<!– DOI: 10.1016/j.clcc.2024.01.003 //–>
https://doi.org/10.1016/j.clcc.2024.01.003
Ho-ho-ho! Gather ’round, my curious elves, for a tale of medical wonder amidst our quest to conquer the pesky villain known as metastatic colorectal cancer (mCRC). In the land of science, a group of intrepid researchers embarked on a frosty expedition, not unlike our own sleigh rides, to discover if certain magical markers in the blood, called angiogenic factors, could predict how well patients would respond to a special concoction of medicines when combined with angiogenesis inhibitors in their second-line (2L) chemotherapy.
From February 2018 to September 2020, these clever elves studied 283 patients who were receiving different potions: some got chemotherapy mixed with a dash of bevacizumab (let’s call it the BEV group), others received FOLFIRI with a sprinkle of ramucirumab (the RAM group), and a third group tried FOLFIRI with a touch of aflibercept (the AFL group). They used a Luminex multiplex assay, a spellbinding tool that can measure multiple factors at once, to analyze the patients’ plasma at the start of treatment and again when the cancer progressed.
What they found was as enchanting as the Northern Lights! Certain factors, like HGF, sNeuropilin-1, sVEGFR-1, and sVEGFR-3, showed a strong interaction with PFS (progression-free survival) between the BEV and RAM groups. For the response rate (RR), sNeuropilin-1 and sVEGFR-1 were the stars of the show. On the other hand, overall survival (OS), PlGF, sVEGFR-1, and sVEGFR-3 were the ones separating the BEV group from the AFL group like good kids from the naughty list.
Now, for a bit of Christmas magic: they could evaluate plasma samples for 203 patients at the time of progression. They noticed that VEGF-A levels, a key factor in tumor growth, went down in the BEV group but went up in the RAM and AFL groups.
So, my dear elves, the story tells us that by looking at pretreatment levels of sVEGFR-1 and sVEGFR-3, we might predict which patients would benefit more from BEV or RAM when mixed with chemotherapy. And if VEGF-A levels rise at progression, it might be better to switch to RAM or AFL, saving BEV for a later line of defense.
And with that, the researchers wrapped up their findings with a bow, under the study number UMIN000028616, adding a little more hope to our stockings this Christmas. Now, let’s get back to our toy-making, but remember, the gift of knowledge is the most precious of all! 🎅🎄